Hemogenyx Pharmaceuticals has ensured a continuation of a pact with a major US biotechnology company for filing of a provisional patent application to the Hemogenyx’s development of a new type of humanized mice with a chimeric mouse-human blood system, which can be used for disease modelling and drug development.
Hemogenyx said that the deal is worth up to approximately $250,000.
The deal is about the application will be used as a tool for drug development and testing. The collaboration, which is expected to last between four to six months, and has the potential to generate further income for Hemogenyx as the collaboration develops.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, said that the US biotechnology company is a leader in the field of blood cancer treatment.
He added: “As we mentioned in our previous announcement, our new type of humanized mice let us extend our work into other disease models and specific drug development. The advancement of this collaboration and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate.”